deltatrials
Completed PHASE1 NCT00003207

Liposomal Doxorubicin and PSC 833 in Treating Patients With AIDS-Related Kaposi's Sarcoma or Other Advanced Cancers

Phase I Study on Doxil and SDZ PSC 833 in the Treatment of AIDS-Associated Kaposi's Sarcoma and Other Advanced Malignancies

Sponsor: National Cancer Institute (NCI)

Conditions Sarcoma Unspecified Adult Solid Tumor, Protocol Specific
Interventions PSC 833 pegylated liposomal doxorubicin hydrochloride
Updated 7 times since 2017 Last updated: Apr 11, 2013 Started: Mar 31, 1998 Primary completion: Jul 31, 2002 Completion: Jul 31, 2002

This PHASE1 trial investigates Sarcoma and Unspecified Adult Solid Tumor, Protocol Specific and is currently completed. National Cancer Institute (NCI) leads this study, which shows 7 recorded versions since 1998 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE1

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE1

  4. Jan 2021 — Jul 2024 [monthly]

    Completed PHASE1

  5. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE1

▶ Show 2 earlier versions

  1. Feb 2017 — Jun 2018 [monthly]

    Completed PHASE1

  2. Jan 2017 — Feb 2017 [monthly]

    Completed PHASE1

    First recorded

Mar 1998

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • St Louis, United States